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Persistence (therapy duration) was defined as number of days between the first and 
last available medication. Adherence was assessed using the medication possession 
ratio (MPR), defined as the number of days with statin therapy on hand divided by 
duration of statin therapy. Results: A total of 3,417 patients met the inclusion 
criteria. The most common statins received were atorvastatin (32.43%), rosuvas-
tatin (22.21%), and pravastatin (20.00%). At initiation, mean(SD) dose (mg/day) was 
9.00(3.66) for atorvastatin, 2.97(1.50) for rosuvastatin, and 9.12(3.09) for pravastatin. 
The percentage of patients with dose titration was low (range: 1.02% for simvastatin 
to 5.01% for rosuvastatin). Mean(SD) persistence ranged from 460.77(270.26) days 
for fluvastatin to 540.08(247.51) days for atorvastatin. Mean(SD) MPR ranged from 
0.90(0.16) for rosuvastatin to 0.95(0.11) for fluvastatin. When MPR was alternatively 
measured over the entire 24 month follow-up period, mean(SD) MPR ranged from 
0.75(0.29) for rosuvastatin to 0.80(0.26) for fluvastatin. ConClusions: Statin titra-
tion among Japanese patients with HRVD was rare, and most patients remained on 
the lowest dosage available during follow-up. Although statin adherence was good, 
these findings raise potential concerns about under-treatment/under-management 
of HRVD in Japan.
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objeCtives: The purpose of this study was to assess patterns and predictors of 
warfarin persistence, discontinuation, and interruption among patients with non-
valvular atrial fibrillation (NVAF). Methods: This study used the MarketScan 
Database and included patients (≥ 18 years of age) with NVAF who were initiated 
on warfarin and followed for 365 days. Persistence was defined as warfarin therapy 
without a gap > 45 days between warfarin prescriptions. Interruption was defined as 
a gap in warfarin therapy > 45 days and ≤ 90 days and discontinuation was defined 
as > 90 days without warfarin therapy. Factors associated with warfarin interrup-
tion/discontinuation were determined using a Cox proportional hazards regres-
sion model. Sensitivity analyses were conducted to assess robustness of results 
by shifting prescription gaps by 7, 14, and 30 days. Results: Within 12 months 
of warfarin initiation, 26,241 (44.8%) patients were persistent with warfarin, 6,895 
(11.8%) had interruption, and 25,457 (43.4%) had discontinuation with or without 
interruption. The risk of warfarin interruption or discontinuation was significantly 
greater in patients that were younger than 65 years (hazard ratio [HR]: 1.22; 95% 
confidence interval [CI]: 1.19-1.25), lived in the West (HR: 1.07; 95% CI: 1.03-1.11), had 
anemia (HR: 1.10; 95% CI: 1.06-1.14), experienced bleeding episodes (HR: 1.10; 95% CI: 
1.06-1.14), were hospitalized or had emergency room visits (HR: 1.11; 95% CI: 1.08-
1.13), or had higher Charlson Comorbidity Index (HR: 1.01; 95% CI: 1.01-1.02). The 
significant factors associated with interruption/discontinuation were consistent 
in the sensitivity analyses. ConClusions: In the usual clinical practice setting, 
more than 50% of patients discontinued or interrupted warfarin within one year 
after initiation. Age < 65 years, multiple medical conditions, and previous hospital 
and ER visits were associated with increased risk of interruption/discontinuation. 
Given the prevalence of warfarin discontinuation/interruption, health care provid-
ers should take a more active role in understanding and addressing the reasons 
behind patient non-persistence.
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objeCtives: The polypharmacy were incidence increase risk of drug-drug interac-
tions, especial suffers from elderly and chronic disease such as age greater than 
60 years old, chronic kidney dysfunction, cardiovascular disease and cancers are 
significant. To evaluate the cost-effectiveness of consultations by pharmacists 
based within primary care polypharmacy in chronic disease. Methods: In order to 
avoid duplication and waste treatment drugs, the plan is to be Pharmaceutical Care 
System and to search medication information at Department of National Health 
Insurance Virtual Private Cloud (VPC). We were identifying potential duplicate medi-
cation from patients with polypharmacy, and to evaluated pharmacist consultations 
on health service use outcome. The study subjects were identified based on inap-
propriate prescriptions of duplicate medications, drug-drug interactions, or over-
dosage. Chi-square test was used for pharmacist consultations on health service 
and cost-effectiveness of data analysis. Results: A total of 68 patients on health 
service with pharmacist consultations were included in this study. The total direct 
medical costs for 24 patients were NT$3,4480 dollars and improved polypharmacy 
related adverse reaction. ConClusions: To develop pharmacist consultations on 
health service is helpful of increase communication and interaction with the pro-
fessional skills of pharmacists and physicians to achieve consensus professional 
and is likely to save costs.
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objeCtives: To determine the quality of life of the patients who underwent angi-
oplasty patients. Methods: This was an open labeled, randomized control trial 
conducted at Kasturba Hospital, Manipal, Karnataka, India. Patients admitted in 
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objeCtives: To study the association between baseline socio-demographic and 
clinical characteristics and total annual follow up cost of unselected patients sub-
jected CRMDs implantation in a real-world setting. Methods: A single-centre, 
prospective study was conducted for one year’s period. In total, 464 consecutive 
patients were recruited (370 were subjected to PM implantation initial or replace-
ment and 94 to ICD implantation initial or replacement). The baseline collected data 
encompasses: socio-demographic characteristics, measurements of anthropometric 
and clinical characteristics; medical history, medications used before the enrolment 
in the study and QoL assessed by the EUROQOL EQ-5D Questionnaire. Resource 
data were assessed at 6 and 12 months after the procedure of implantation. Then, 
the components of cost were calculated using the bottom-up approach. Results: 
The generalized linear model indicated that among the variables considered, only 
age, history of hypertension and hypercholesterolaemia are significantly associ-
ated with the total annual social cost of patients subjected to PM implantation. 
The predicted mean total annual costs (95% CI) adjusted for the factors mentioned 
above were € 2.256 (€ 2.018–€ 2.534) for the overall sample of PM patients, and € 2.171 
(€ 1.888–€ 2.505) and € 2.409 (€ 2.063–€ 2.778) in patients with initial PM implantation 
and those subjected to PM replacement, respectively. In addition, the history of 
hypertension and hypercholesterolaemia as well as the baseline QoL were signifi-
cantly associated with the total annual cost of patients subjected to ICD implan-
tation. The predicted mean total annual costs (95% CI) adjusted for the factors 
mentioned above were € 3.318 (€ 2.771–€ 3.967) for the overall sample of ICD patients, 
and 3.528 (€ 2.901– € 4.156) and € 2.044 (€ 1.329–€ 3.029) in patients with initial ICD 
implantation and those subjected to ICD replacement, respectively. ConClusions: 
Age, history of hypertension and hypercholesterolaemia for the patients were sub-
jected to PM implantation and moreover the quality of life for the patients were 
subjected to ICD are significantly associated with the total annual social cost.
CarDioVasCular DisorDers – Patient-reported outcomes & Patient  
Preference studies
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objeCtives: Uncontrolled blood pressure (BP) attributed to medication non-adher-
ence may increase the risk of complications and death. Predicting hypertensive 
patients’ medication adherence, therefore, is an important factor. The theory of 
planned behavior (TPB) proposes that the hypertensive patient’s attitude, subjective 
norm, and perceived behavioral control predict intention to perform behavior, leading 
to prediction of medication adherence. Methods: 604 outpatients with established 
chronic hypertension from a regional hospital in eastern Taiwan were enrolled in this 
study. Using a cross-sectional study, BP was measured and structured questionnaires 
were delivered to all participants. Descriptive statistics were calculated for all meas-
ures as appropriate. To assess differences among the adherence and poor adherence 
groups by demographic, TPB variables and BP, Chi-Square test and Fisher’s exact test 
for categorical variables or analysis of variance tests for continuous variables were 
performed. The medication adherence, TPB variables and BP were analyzed using 
correlation coefficient. All data were analyzed using SPSS 20.0 statistical analysis 
software. Results: The mean of adherence scores was 2.6 (sd= 2.4). Adherence and 
poor adherence of patients accounted for 57.5% and 42.5%, respectively. Intention was 
positively correlated with attitude (r= 0.23, p= 0 .00), subjective norm (r= 0.27, p= 0 .00), 
and perceived behavior control (r= 0.53, p= 0 .00). Adherence was positively correlated 
with intention (r= 0.49, p= 0 .00). When SBP and DBP were considered separately, 
adherence was significantly different between the good and poor controls of SBP and 
DBP. The two adherence groups were positively correlated with SBP control (r= 0.09, 
p= 0 .02) and DBP control (r= 0.10, p= 0.01). ConClusions: Hypertensive patients’ 
attitudes, subjective norms, and perceived behavioral controls predict intentions, 
leading to prediction of medication adherence. Medication adherence has significant 
impact on the SBP and the DBP control. These results suggest that application of TPB 
is useful to predict medication adherence in Taiwanese patients.
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objeCtives: To document dose titration, persistence, and adherence among 
patients with high-risk vascular disease (HRVD) receiving statin therapy in an 
employed Japanese population. Methods: A retrospective analysis was con-
ducted using the Japan Medical Data Center (JMDC) database, which contained 
inpatient, outpatient, and pharmacy claims of 800,000 lives from 2006–2011. HRVD 
was identified based on diagnoses for cerebrovascular disease, peripheral artery 
disease, coronary artery disease with diabetes, and history of acute coronary syn-
drome (ACS) (with an ACS claim > 30–≤ 365 days after ACS-related hospitalization) 
between 1/1/2008–12/31/2009. Patients were required to have insurance coverage 
for ≥ 12 months before and ≥ 24 months after first HRVD claim. Patients receiving 
statin therapy were selected to assess dose titration, persistence, and adherence. 
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objeCtives: Despite increasing prevalence of venous thromboembolism (VTE) in 
China, real-world use of anticoagulants in clinical practice is not well understood. 
This study aims to assess treatment pattern and anticoagulant monitoring among 
hospitalized VTE patients in China. Methods: Hospitalizations with a diagnosis of 
VTE (including deep vein thrombosis (DVT) or pulmonary embolism (PE)) between 
January 1st, 2010 and June 30th, 2013 were identified from a large electronic medical 
record database containing 100% inpatient records from two tertiary hospitals in two 
major cities. Analyses were performed to describe anticoagulant treatment among 
all VTE-related hospitalizations and international normalized ratio (INR) monitoring 
among hospitalizations where warfarin was used. Multivariate regressions were per-
formed to assess factors associated with oral anticoagulant use, including type of VTE, 
patient demographics, comorbidities, insurance status, VTE diagnosis type, admission 
condition, ordering department, and surgical procedure. Results: Among a total of 
1,047 VTE-related hospitalizations, mean age at hospitalization was 62.4 years, 54.1% 
of hospitalizations occurred to men, and 77.1% were DVT-related hospitalizations. 
About 46.3% hospitalizations used heparin only, 35.0% used warfarin (with or without 
heparin), 0.8% used rivaroxaban, and 18.0% did not use any anticoagulant. Among 
hospitalizations where warfarin was used, 90.8% received at least one INR test before 
discharge; among hospitalizations with INR results available, 30.0% had the last INR 
during hospitalization within target therapeutic range (2 to 3). Diagnosis of PE (vs. 
DVT), female, cardiovascular as ordering department, having surgical procedures, 
comorbidity of chronic pulmonary disorder, and VTE as primary diagnosis were sig-
nificantly associated with higher oral anticoagulant use (all P < 0.05). ConClusions: 
In China, use of innovative oral anticoagulants is limited among hospitalized VTE 
patients. Under-monitoring and suboptimal care may be an issue for hospitalized 
patients treated with warfarin. These findings reveal gaps in clinical practice and 
unmet needs among hospitalized patients with VTE in China.
PCV53
Drug utilization researCh in geriatriC Patients With ChroniC 
isChemiC heart Disease
Dorjbal E.
Health Sciences University, Ulaanbaatar, Mongolia
objeCtives: Study potentially inappropriate drug use of geriatrics and medica-
tions, which were used for the 65 years and older in-patients, with chronic ischemic 
heart disease, of some tertiary level hospitals. Methods: The retrospective study 
involved 65 and over aged 438 in-patients randomly collected records, who were 
treated at I, II and III state hospitals, in 2010-2012, with Chronic ischemic heart 
disease/CIHD/. Results: The 2nd and 3rd hospitals commonly use aspirin as an 
anti-platelet agent whereas the 1st state hospital uses dipyridamole, clopidogrel 
with aspirin. To improve coronary circulation and decrease the heart pain the 2nd 
(55%) and 3rd (64%) state hospitals use nitrates, but the 1st state hospital had no 
evidence of using this group medication for the patients with CIHD. 1st state hos-
pital regularly uses beta-blockers (61%) for decreasing cardiac oxygen demand and 
improves heart microcirculation. The angiotensin converting enzyme and diuretic 
group medications were more used in 1st and 3rd state hospitals. 1365 medications 
were used (n= 149) and 331 (24.2%) of them was potentially inappropriate medica-
tions and related to the 1st group of Beers criteria. In the 2nd state hospital:1007 
medications: 204 (20%) - potentially inappropriate medications and 194 (19%)- 1st 
group drugs of Beers criteria; the 3rd state hospital - 1162 medications:151 (13%) – 
potentially inappropriate medications. ConClusions: The 30.1%-48.5% of the total 
medications, prescribed for CIHD, in the tertiary hospitals, were agreed with CIHD 
therapeutic and diagnosis guidelines. 50% of the total medications used for CIHD, 
were accompanied diagnoses and other drugs.
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objeCtives: Lipid control is crucial in patients undergoing percutaneous coro-
nary intervention (PCI). Lipid guidelines recommend that all patients with coronary 
heart disease should have low density lipoproteins cholesterol (LDL-C) goals to 
be < 100 mg/dl with the ideal therapeutic option < 70 mg/dl. The primary objec-
tive of this research was to evaluate the success rate of lipid control during the 
six months after PCI. Methods: We conducted a retrospective, observational 
study on all patients who underwent PCI at a large urban hospital in Shanghai, 
China from 5/2010 to 6/2011. Patients who had lipid measures at 30-day or 180-day 
follow-ups were included in the analysis. Percentages of patients that achieved 
LDL-C treatment goals of < 100 and < 70 were assessed, respectively. Statin use 
was also reported. Results: A total of 119 patients (82.4% male) were included in 
this analysis. The mean age was 64 years (range 40 to 90). Overall, 69.8% of patients 
had angina, 63.9% hypertension, 29.4% diabetes, 22.7 % previous myocardial infarc-
tion, 16.0% hyperlipidemic pancreatitis, and 9.2% chronic kidney disease. 52.9% of 
patients were active smokers or previously smoked and PCI was not the first time for 
10.9% of patients. After PCI, all but one patient at 30-day follow-up, and all patients 
at 180-day follow-up, reported use of statins. The proportion of patients meeting 
minimum LDL-C goal (< 100) decreased slightly from 69.1% at 30-day follow-up to 
67.9% at 180-day follow-up; the percentage of patients meeting ideal LDL-C goal 
(< 70) decreased substantially from 30.9% to 23.9% among all patients, and from 
43.4% to 32.1% (p< 0.05) among male aged 60 years or older. ConClusions: Despite 
statin treatment, at least 30% of patients were not at the recommended LDL-C goal 
of < 100 mg/dl six months post PCI and only one quarter of these high risk patients 
were at the optimal goal of < 70 mg/dl.
the cardiology wards with unstable angina and myocardial infarction and under-
went angioplasty procedure, were randomized into control group where, standard 
care is provided and Intervention group where, Pharmaceutical care was provided 
with tailor made counseling about diseases, drugs, diet and lifestyle modifications. 
Quality of Life assessment was done with EQ 5D 5L and MacNew Questionnaires by 
interview method at 3 months, 6 months, 9 months and at 12 months. Results: 213 
participants were randomized into control group (n= 105) and intervention group 
(n= 108). Socio-demographic characteristics at baseline are similar between two 
groups. At baseline, Global Scores of MacNew questionnaire of both the groups have 
similar scores (3.03 ± 1.29 & 2.89 ±1.12). At 12 months, scores of 2.32 ±0.91 and 5.47 ± 
1.45 were observed for control and intervention group respectively. EQ utility values 
at base line were 0.46 ± 0.17 and 0.47 ± 0.16. At 12 months, utility values were 0.11 
± 0.20 and 0.68 ± 0.23 observed for control and intervention group respectively. EQ 
Visual analog scores at base line were 59.57 ± 14.51 and 61.01 ± 13.34. At 12 months, 
scores of 73.38 ± 5.19 and 85.13 ± 4.62 was observed for control and interventional 
groups respectively. Domains of the both questionnaire are evaluated and there was 
a significant change in the intervention group specifically, physical, emotional and 
social domains. Quality adjusted life years were 0.7114 and 0.8582 for control and 
intervention groups respectively. ConClusions: Pharmaceutical care significantly 
improves the quality of life of the patients who underwent angioplasty procedure.
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objeCtives: Obesity is reported to be underlying cause of metabolic syndrome 
and associated with hypertension and diabetes .A BMI (body mass index) of more 
than 30 places individuals in obese category. Majority of urban Indian population 
is categorized being overweight (BMI greater than 25). A sedentary lifestyle and lack 
of exercise in Indian cities causes belly fat accumulation which is reported to be a 
risk factor for metabolic diseases. Methods: In this study, we have categorized 
middle class Indian population (test subjects > 500) residing in metropolitan Delhi 
area into different age groups (11-20, 21-30, 31-40, 41-50, 51-60 and 60 and above) 
and recorded BMI and degree of belly fat present (no excess belly fat, small, medium 
and high). Our data shows that age groups 11-20 and 21-30 show normal BMI and 
lower cases of accumulated belly fat whereas there is a significant increase (50%) 
in BMI and presence of belly fat in age group 31-40 and above. We also recorded 
presence of obesity related metabolic disorders such as diabetes and hypertension 
in the above mentioned age groups. Results: Test subjects in all age groups with 
BMI > 25 (over-weight and obese) recorded presence of related disorders (39.40% in 
over-weight and 67.34% in obese classes). Most prevalent diseases with higher BMI 
were hypertension, diabetes, and joint pain in decreasing order. ConClusions: 
The sudden increase in obesity related factors is a matter of concern in the age 
group of 30 and above. We conclude that decrease in physical activity and sedentary 
lifestyle is the cause of belly fat accumulation and onset of obesity which results 
in metabolic diseases such as hypertension and diabetes. This information is most 
relevant for social awareness about obesity in middle class Indian population and 
through this study, it has been possible to alert the test subjects about risk of asso-
ciated disorders.
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objeCtives: Obesity was said to be one of the important risks for mortality. 
Inconsistent findings have been reported in the association between obesity and 
quality of life. The study provides a finding in the question using a cross-sectional 
survey conducted in China. Methods: A total of 1,281 hypertensive residents in 
China aged 35 years or older were included in the analysis. The short-form 36 (SF-36) 
was used to measure the quality of life. It consisted of physical and mental domains. 
The highest score was 100 and 0 for the lowest in each domain. Level of obesity 
was classified using body mass index (BMI), namely, lean (< 18.5), normal (18.5-24), 
overweight (24-28), obese (over 28) according to the Chinese classification. Means of 
physical and mental domains were calculated for the degree of obesity, adjusted for 
age, gender, marital status, education level, and exercise habits. Difference in quality 
of life among the levels of obesity was tested by the analysis of variance. Results: 
There were lean (n= 34), normal (n= 531), overweight (n= 521), obese (195) subjects 
with hypertension. Men occupied 53% and 37% for aged 60 years or older. Significant 
risk factors lowering the quality of life were women, elderly, low education and 
exercise. Adjusted mean (±standard error) of physical domain was 64±3.3 (lean), 
70±1.2 (normal), 71±1.2 (overweight), 71 ±1.6 (obese), where the p-value was 0.17. 
Whereas, the adjusted mean of mental domain was 69±3.3 (lean), 72±1.1 (normal), 
76±1.2 (overweight), 76±1.6 (obese), where the p-value was 0.018. ConClusions: 
A significant increase in the mental component of quality of life was found accord-
ing to the level of obesity; however no trend was observed in the physical compo-
nent.
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